Since the first approval of the immune checkpoint inhibitor ipilimumab for melanoma, which targets the anti CTLA-4 checkpoint, different immune checkpoint inhibitors that target a PD-1 or PDL-1 for a wide range of cancer indications has been described (Robert 2020). Here, CD274 is linked to cancer.